Radionuclide diagnosis and therapy of thyroid cancer: Current status report

Seminars in Nuclear Medicine

Volumn 15, Issue 2, 1985, Pages 106-131

  Freitas, John E ^a,b   Gross, Milton D ^a,b   Ripley, Shawn ^a,b   Shapiro, Brahm ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; PERTECHNETIC ACID TC 99M; RADIOACTIVE IODINE;

ADENOCARCINOMA; ADULT; FEMALE; HEAD AND NECK TUMOR; HUMAN; LUNG TUMOR; MALE; METASTASIS; PAPILLARY CARCINOMA; REVIEW; SCINTISCANNING; THYROID TUMOR; THYROIDECTOMY;

ADENOCARCINOMA; ADULT; CARCINOMA, PAPILLARY; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGE; SODIUM PERTECHNETATE TC 99M; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 0022048882     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-2998(85)80021-0     Document Type: Article

References (132)

1. Cancer statistics
2. Significance of solitary nontoxic thyroid nodules
3. The problem of malignancy in nodular goiter: Recapitulation and challenge
4. The scintillation counter in clinical studies of human thyroid physiology using I-131
5. Instrumentation for I-131 use in medical studies
6. Visual delineation of thyroid gland in vivo
7. A study of the histopathology and physiologic function of thyroid tumors using radioactive iodine and radioautography
8. The function of various types of thyroid carcinoma as revealed by the radioautographic demonstration of radioactive iodine (I-131)
9. Spontaneous and experimentally induced uptake of radioactive iodine in metastases from thyroid carcinoma A preliminary report
10. The effect of total thyroidectomy on the function of metastatic thyroid cancer
11. Behavior of the thyroid toward elements of the seventh periodic group
12. Pertechnetate 99m localization in man with applications to thyroid scanning and study of thyroid physiology
13. 75Selenomethionine and radionuclide
14. 67Ga-citrate
15. 67Ga-citrate and the non-functioning thyroid nodule
16. Clinical experience of tumor imaging with 201-Tl chloride
17. Thallium-201 chloride thyroid scintigraphy to evaluate benign and/or malignant nodules
18. The scintillation camera with pinhole collimator in thyroid imaging
19. Improved methods for thyroid scanning: A correlation with surgical findings
20. Fluorescent-thyroid scanning
21. Pathology in thyroid cancer
22. Occult papillary carcinoma of the thyroid gland A study of 140 cases observed in a 30 year period
23. The prevalence of small papillary thyroid carcinomas in 100 consecutive necropsies in an American population
24. Prevalance and significance of occult thyroid cancer
25. Thyroid carcinoma: Current controversies
26. Risk factor analysis in differentiated thyroid cancer
27. Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients
28. Retrospective study of 820 patients treated for papillary carcinoma of the thyroid at the Mayo Clinic between 1946 and 1971
29. Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: Statistics following University of Michigan therapy
30. Prediction of mortality in papillary thyroid cancer
31. Total thyroidectomy in the treatment of thyroid carcinoma
32. The thyroid nodule
33. Cancer in thyroid nodules
34. The thyroid nodule
35. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood
36. Natural history of radiation-associated thyroid cancer
37. The solitary thyroid nodule. A reassessment
38. The malignant “cold” nodule of the thyroid
39. MEN type IIA syndrome: Dilemmas in modern management
40. Functioning thyroid masses in childhood and adolescence. Clinical, surgical and pathological correlations
41. Papillary thyroid carcinoma in a toxic adenoma
42. The occurrence of carcinoma in “hot” thyroid nodules
43. Comparison of 99m Tc-pertechnetate and 131-I in scanning of thyroid nodule
44. Disparate thyroid imaging. Combined studies with sodium pertechnetate Tc-99m and radioactive iodine
45. Histopathology of thyroid lesions that caused discrepant findings between Tc-99m and I-123 scan
46. Clinical importance of the “indeterminate” nodule in thyroid imaging: The commonest cause of the “false negative” thyroid imaging study
47. Thyroid cancer occurring as a late consequence of head and neck irradiation
48. Radiation exposure and thyroid cancer
49. Irradiation-related thyroid cancer: Information for Physicians
50. Irradiation-related thyroid cancer
51. Scintigraphic thyroid abnormalities after radiation: A controlled study with Tc-99m pertechnetate scanning
52. Significance of extrathyroidal uptake of Tc-99m and I-123 in the thyroid scan: Concise communication
53. Applying the radioactive eraser: I-131 to ablate normal thyroid tissue in patients from whom thyroid cancer has been resected
54. Influence of triiodothyronine withdrawal time on I-132 uptake post-thyroidectomy
55. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma
56. Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: Implications for I-131 treatment of thyroid carcinoma
57. Low iodine diet in I-131 ablation of thyroid remnants
58. Prolonged iodine clearance with a depletion regimen for thyroid carcinoma: Concise communication
59. The diagnostic and therapeutic value of thyrotropin hormone and heavy dosage scintigrams for the demonstration of thyroid cancer metastases
60. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: Concise Communication
61. The use of radioiodine in the management of the differentiated thyroid cancer
62. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers
63. Prognostic value of the I-131 whole body scan in postsurgical therapy for differentiated thyroid cancer
64. Radioimmunoassay for measurement of thyroglobulin in human serum
65. Comparison of serum thyroglobulin with iodine scans in thyroid cancer
66. Critical evaluation of serum thyroglobulin levels and I-131 scans in post-therapy patients with differentiated thyroid carcinoma: Concise communication
67. A sensitive human thyroglobulin RIA to define clearly the presence or absence of functioning thyroid tissue
68. Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: Concise communication
69. Thyroglobulin assay in the follow-up of patients with differentiated thyroid carcinomas: Comparison of its value in patients with or without normal residual tissue
70. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer
71. Serum thyroglobulin in thyroid cancer
72. Changing clinical, pathologic, therapeutic and survival patterns in differentiated thyroid carcinoma
73. Selection of surgical treatment for well-differentiated thyroid carcinomas
74. Surgical management of papillary and follicular carcinoma of the thyroid
75. Thyroid carcinoma. Classification, intraglandular dissemination and clinicopathological study based upon whole organ sections of 80 glands
76. Multicentricity of papillary adenocarcinoma of the thyroid Influence on treatment
77. Total thyroidectomy for cancer of the thyroid Significance of intraglandular dissemination
78. The morbidity of total thyroidectomy
79. Radioiodine tracer studies after total thyroidectomy
80. Interpretation of scintigrams obtained after thyroidectomy
81. Radioiodine I-131 therapy in the management of thyroid cancer
82. Feasibility of total thyroidectomy in the treatment of thyroid carcinoma
83. Cervical distribution of iodine-131 following total thyroidectomy for thyroid cancer
84. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine
85. The treatment of thyroid carcinoma with radioactive iodine
86. An analysis of “Ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: Experience at the University of Michigan
87. I-131 therapy in differentiated thyroid carcinoma
88. Thyroid neoplasia
89. Controversies in the treatment of thyroid cancer: The New York Memorial Hospital approach
90. The use of radioiodine in the management of thyroid cancer
91. Thyroid neoplasms
92. Treatment of thyroid carcinoma with I-131
93. Radioiodine therapy of thyroid cancer
94. Treatment of thyroid cancer
95. Thyroid cancer
96. Treatment of thyroid cancer: Death rates after surgery and after surgery followed by sodium iodides, I-131
97. Treatment of metastatic thyroid cancer
98. Low-dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer
99. Failure of low doses of I-131 to ablate residual thyroid tissue following surgery for thyroid cancer
100. Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma
101. Comparison of 30 and 50 mCi doses of iodine-131 for thyroid ablation
102. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: Concise communication
103. Ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer can be achieved with less whole body radiation
104. The ablation of normal thyroid tissue with iodine-131
105. Current status of radioiodine (I-131) treatment of hyperthyroidism
106. Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors: Absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma
107. The role of TRH and lithium in the management of thyroid cancer
108. Human reaction to bovine TSH: Concise communication
109. Effect of a low iodine diet on I-131 therapy in follicular thyroid carcinomata
110. Diuretic augmentation of I-131 uptake in inoperable thyroid cancer
111. Treatment of malignant thyroid diseases
112. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer
113. External radiotherapy and radioiodine in the treatment of thyroid cancer
114. The role of external radiation in the management of papillary and follicular thyroid cancer
115. Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience
116. Unusual types of hyperthyroidism
117. Hyperthyroidism due to functioning metastatic thyroid carcinoma: Precipitation of thyroid storm with therapeutic radioactive iodine
118. Radiation sickness in man following the administration of therapeutic radioiodine Relationship between latent period dose rate and body size
119. Bone metastases of thyroid cancer, biological behavior and therapeutic possibilities
120. Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-131
121. Azoospermia after iodine-131 treatment for thyroid carcinoma
122. The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine
123. Subsequent fertility and birth histories of children and adolescents treated with I-131 for thyroid cancer
124. Pure follicular thyroid carcinoma: Impact of therapy in 214 patients
125. Papillary thyroid carcinoma: The impact of therapy in 576 patients
126. Prospects from the treatment of thyroid carcinoma with radioiodine
127. Differentiated thyroid carcinomas. Treatment of distant metastases
128. The effect of I-131 therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma
129. Pulmonary metastases in differentiated thyroid carcinoma
130. Thyroid carcinoma treated with radioiodine